Health Economics›Breast cancer›Metastatic disease subsequent lines of therapy

Metastatic disease subsequent lines of therapy

Breast cancer · 34 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 24 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Fulvestrant and Ribociclib Variant #01	ER	R 37 135	28d	20.5 mo	60.7 mo	23	R 854 110 PFS proxy	3
Abemaciclib and Fulvestrant Variant #01	ER	R 32 245	28d	11.4 mo	46.7 mo	13	R 419 183 PFS proxy	4
Fulvestrant and Palbociclib Variant #01	ER	R 26 181	28d	10.6 mo	34.8 mo	12	R 314 169 PFS proxy	3
Eribulin monotherapy Variant #01	ER	R 24 243	21d	4.1 mo	13.1 mo	6	R 145 460 PFS proxy	21
Eribulin monotherapy Variant #01	TNBC	R 24 243	21d	4.1 mo	13.1 mo	6	R 145 460 PFS proxy	21
Abemaciclib monotherapy Variant #01	ER	R 21 226	28d	—	—	—	—	—
Everolimus and Exemestane Variant #01	ER	R 19 245	28d	7.8 mo	31.0 mo	9	R 173 206 PFS proxy	2
Everolimus and Tamoxifen Variant #01	ER	R 18 496	28d	—	—	—	—	1
Capivasertib and Fulvestrant Variant #01 Partial	ER	R 16 325	28d	7.3 mo	—	8	R 130 601 PFS proxy	2
Capecitabine and Ixabepilone Variant #01	TNBC	R 15 711	21d	5.8 mo	16.4 mo	9	R 141 400 PFS proxy	4
Enzalutamide monotherapy Variant #01	TNBC	R 14 528	28d	~4.2 mo	~17.5 mo	~5	~R 72 642 PFS proxy · indirect	13
Gemcitabine monotherapy Variant #20	TNBC	R 14 213	56d	4.6 mo	11.2 mo	3	R 42 639 PFS proxy	15
Gemcitabine monotherapy Variant #20	ER	R 14 213	56d	4.6 mo	11.2 mo	3	R 42 639 PFS proxy	15
Capecitabine and Fulvestrant Variant #01	ER	R 11 464	28d	—	—	—	—	—
Anastrozole and Fulvestrant Variant #01	ER	R 11 043	28d	4.4 mo	—	5	R 55 213 PFS proxy	1
Fulvestrant monotherapy Variant #03	ER	R 10 883	28d	5.5 mo	30.4 mo	6	R 65 301 PFS proxy	31
Exemestane and Palbociclib Variant #01	ER	R 10 741	28d	5.7 mo	—	7	R 75 187 PFS proxy	1
Letrozole and Palbociclib Variant #01	ER	R 10 226	28d	5.7 mo	—	7	R 71 585 PFS proxy	1
Anastrozole and Palbociclib Variant #01	ER	R 10 015	28d	5.7 mo	—	7	R 70 103 PFS proxy	1
Mitomycin and Vinblastine (MV) Variant #02	—	R 7 939	56d	2.5 mo	8.7 mo	2	R 15 878 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	TNBC	R 3 663	21d	4.1 mo	—	6	R 21 978 PFS proxy	1
Exemestane monotherapy Variant #01	ER	R 2 846	90d	3.6 mo	—	2	R 5 693 PFS proxy	7
Capecitabine monotherapy Variant #17	ER	R 2 219	21d	4.5 mo	15.6 mo	7	R 15 535 PFS proxy	33
Capecitabine monotherapy Variant #17	TNBC	R 2 219	21d	4.5 mo	15.6 mo	7	R 15 535 PFS proxy	33
Exemestane and Tucidinostat Variant #01 Partial	ER	R 886	28d	7.4 mo	—	9	R 7 970 PFS proxy	1
Vinorelbine monotherapy Variant #01	TNBC	R 583	21d	4.0 mo	10.8 mo	6	R 3 500 PFS proxy	17
Vinorelbine monotherapy Variant #01	ER	R 583	21d	4.0 mo	10.8 mo	6	R 3 500 PFS proxy	17
Tamoxifen monotherapy Variant #06	ER	R 410	28d	—	32.9 mo	—	—	1
Letrozole monotherapy Variant #01	ER	R 371	28d	—	—	—	—	1
Anastrozole monotherapy Variant #01	ER	R 159	28d	—	—	—	—	1
Fluoxymesterone and Tamoxifen Variant #01 Partial	ER	R 137	28d	—	—	—	—	—
Elacestrant monotherapy Variant #01 Partial	ER	—	28d	—	—	—	—	1
Sacituzumab govitecan monotherapy Variant #01 Partial	ER	—	21d	5.2 mo	13.2 mo	8	—	8
Sacituzumab govitecan monotherapy Variant #01 Partial	TNBC	—	21d	5.2 mo	13.2 mo	8	—	8

34 of 34 regimens shown